A Self‐Assembled Transdermal Nanomedicines Incorporating Pendant Disulfides for Non‐Invasive, Synergistic Treatment of Melanoma
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202402685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Junjie Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: New Cornerstone Science Laboratory, MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, Fuzhou University, Fu…. Hauptthemen laut MEDLINE: Disulfides, Administration, Cutaneous, Pyridones, Pyrimidinones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Fujian Province, Major Project of Science and Technology of Fujian Province.
Abstract (Originalsprache)
Transdermal drug delivery system (TDDS) offers lower systemic toxicity and good patient compliance, making it a promising treatment option for skin‐related cancers. However, physiological barriers in the skin frequently impede the therapeutic efficiency of TDDS. To address this, a unique self‐assembled TDDS that incorporates disulfide pendant groups (termed Sup‐TDDS) is presented. It is formulated with dithiolane‐containing lipoic acid (LA), photosensitizers Ce6, and chemotherapeutic agents trametinib. Pendant disulfide moieties on Sup‐TDDS facilitate thiol‐disulfide exchange reactions with exofacial thiols on cell surfaces, thus enhancing stratum corneum penetration. In contrast to intravenous injection, topical administration of Sup‐TDDS can penetrate deeper into the skin (> 500 µm) and promote drug accumulation in subcutaneous tumors. In a B16F10‐bearing mouse model, Sup‐TDDS treatment demonstrates significant anti‐tumor effects in primary and recurrent melanoma, benefiting from the synergistic effects of Ce6 and trametinib. These results underscore that Sup‐TDDS's transdermal properties allow non‐invasive melanoma therapy, implying the potential of nanodrugs containing pendant disulfides for transdermal treatment of skin illnesses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- New Cornerstone Science Laboratory, MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350108, China.
- Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, The School of Pharmacy, Fujian Medical University, Fuzhou, 350122, China.
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350108, China.
ORCID-Profile: Jingying Li
Förderung
- National Natural Science Foundation of China
- Science Fund for Distinguished Young Scholars of Fujian Province
- Major Project of Science and Technology of Fujian Province
- Science and Technology Project in Fujian Province of China
- Key Technologies Research and Development Program
Zitieren
APA
Zhang, J., Peng, C., Liu, S., Lian, Z., Zhou, J., Li, J., & Yang, H. (2024). A Self‐Assembled Transdermal Nanomedicines Incorporating Pendant Disulfides for Non‐Invasive, Synergistic Treatment of Melanoma. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402685
Vancouver
Zhang J, Peng C, Liu S, Lian Z, Zhou J, Li J, et al. A Self‐Assembled Transdermal Nanomedicines Incorporating Pendant Disulfides for Non‐Invasive, Synergistic Treatment of Melanoma. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202402685
BibTeX
@article{Zhang2024,
author = {Zhang, Junjie and Peng, Changkun and Liu, Shuya and Lian, Zhijie and Zhou, Jie and Li, Jingying and Yang, Huanghao},
title = {A Self‐Assembled Transdermal Nanomedicines Incorporating Pendant Disulfides for Non‐Invasive, Synergistic Treatment of Melanoma},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202402685}
}
EUVIMED